Holen Sie sich die Stockscreener-App
6.14
5.25%
-0.34
Schlusskurs vom Vortag:
$6.48
Offen:
$6.53
24-Stunden-Volumen:
2.84M
Relative Volume:
1.85
Marktkapitalisierung:
$854.23M
Einnahmen:
$62.04M
Nettoeinkommen (Verlust:
$-533.34M
KGV:
-1.5663
EPS:
-3.92
Netto-Cashflow:
$-473.07M
1W Leistung:
-6.26%
1M Leistung:
+11.84%
6M Leistung:
+20.39%
1J Leistung:
-16.46%
1-Tages-Spanne:
$6.00
$6.75
1-Wochen-Bereich:
$6.00
$6.97
52-Wochen-Spanne:
$4.155
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
Firmenname
Vir Biotechnology Inc
Sektor
Branche
Telefon
415-906-4324
Adresse
1800 OWENS STREET, SAN FRANCISCO, CA
Vergleichen Sie VIR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
6.14 | 901.53M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Eingeleitet | Evercore ISI | Outperform |
| 2025-08-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-03-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Eingeleitet | SVB Leerink | Outperform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-03-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-01-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-09-14 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-11 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Eingeleitet | Needham | Buy |
| 2020-03-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-02-27 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2019-11-05 | Eingeleitet | Barclays | Overweight |
| 2019-11-05 | Eingeleitet | Cowen | Outperform |
| 2019-11-05 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten
Vir Biotechnology stock gains on Norgine partnership for Hepatitis Delta program - Investing.com UK
Latham Advises Norgine on Exclusive Licensing Agreement With Vir Biotechnology - Latham & Watkins LLP
Norgine Pharmaceuticals Limited - AD HOC NEWS
EQS-News: Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnologyboerse.de - boerse.de
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology - PR Newswire
Vir Biotechnology Licenses CHD Combination Therapy to Norgine for Europe, Australia, New Zealand - marketscreener.com
Vir Biotechnology issues license to Norgine to market hepatitis D candidate - Seeking Alpha
Vir Biotechnology Secures Licensing Deal with Norgine - TipRanks
Vir Biotechnology licenses hepatitis delta treatment to Norgine in €550m deal - Investing.com Canada
Vir Biotechnology licenses hepatitis delta treatment to Norgine in €550m deal By Investing.com - Investing.com South Africa
Vir Biotechnology (VIR) Secures Exclusive Licensing Deal with No - GuruFocus
Vir Biotechnology stock rises after licensing hepatitis delta treatment By Investing.com - Investing.com Canada
Vir Biotechnology grants Norgine exclusive commercial license to chronic hepatitis delta treatment candidate - marketscreener.com
Vir Biotechnology Grants Norgine Exclusive Commercial License To Chronic Hepatitis Delta Treatment Candidate - TradingView — Track All Markets
Vir Biotechnology signs agreement with Norgine for hepatitis Delta treatment - Traders Union
Vir Biotechnology grants Norgine exclusive license for hepatitis delta treatment - StreetInsider
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program - Business Wire
12,916,663 Shares in Vir Biotechnology, Inc. $VIR Bought by ARCH Venture Management LLC - MarketBeat
Vir Biotechnology stock gets positive readthrough from Mirum’s Bluejay deal By Investing.com - Investing.com Canada
Vir Biotechnology stock gets positive readthrough from Mirum’s Bluejay deal - Investing.com
After Losing 25% in the Past Year, Vir Biotechnology, Inc. (NASDAQ:VIR) Institutional Owners Must Be Relieved by the Recent Gain - 富途牛牛
Vir Biotechnology (VIR) Gains Positive Outlook Amid Industry Acq - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Shares Gap UpShould You Buy? - MarketBeat
Vir Biotechnology Insiders Sold US$1.1m Of Shares Suggesting Hesitancy - simplywall.st
Can Vir Biotechnology (NASDAQ:VIR) Afford To Invest In Growth? - Yahoo Finance
Is Alnylam Pharmaceuticals a Millionaire Maker? - The Motley Fool
Is Vir Biotechnology Inc a good long term investmentRSI Overbought/Oversold & Rapid Wealth Accumulation - earlytimes.in
Insider Selling: Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells 191,854 Shares of Stock - MarketBeat
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Insider Selling: Vir Biotechnology (NASDAQ:VIR) Director Sells 22,000 Shares of Stock - MarketBeat
Vir Biotechnology, Inc. (VIR) Stock Forecasts - Yahoo! Finance Canada
Vir Biotechnology (NASDAQ:VIR) Shares Gap Down After Insider Selling - MarketBeat
What drives Vir Biotechnology Inc stock priceStochastic Oscillator Alerts & You’ve Never Seen Stock Picks Like These - earlytimes.in
Vir Biotechnology director Sato sells $132k in stock By Investing.com - Investing.com UK
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Vir Biotechnology director Sato sells $132k in stock - Investing.com
Vir Biotechnology Director Sells 22,000 Shares - TradingView
Chmn Sato Sells 22,000 ($132.1K) Of Vir Biotechnology Inc [VIR] - TradingView
Endurance (Cayman) Ltd Svf Sells 61,493 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Insider Selling: Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells 127,938 Shares of Stock - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Shares Down 7.1%What's Next? - MarketBeat
Vir Biotechnology (VIR) Stock Analysis Report | Financials & Insights - Benzinga
Owner SVF Endurance (Cayman) Ltd Sells 189,431 ($1.2M) Of Vir Biotechnology Inc [VIR] - TradingView — Track All Markets
Vir Biotechnology Reports Q3 2025 Financial Results and Clinical Progress - MSN
Why analysts remain bullish on Vir Biotechnology Inc. stockJuly 2025 Gainers & Precise Swing Trade Entry Alerts - moha.gov.vn
Ensign Peak Advisors Inc Increases Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology’s Earnings Call: Achievements and Challenges - MSN
Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 227,803 Shares - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 235,971 Shares - MarketBeat
Owner SVF Endurance (Cayman) Ltd Sells 463,774 ($2.9M) Of Vir Biotechnology Inc [VIR] - TradingView
SVF Endurance reports Vir (VIR) insider sales around $6 per share - Stock Titan
Finanzdaten der Vir Biotechnology Inc-Aktie (VIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):